Which act required child-resistant packaging for both prescription and nonprescription drugs?

The Poison Prevention Packaging Act is the legislation that mandated the use of child-resistant packaging for both prescription and nonprescription drugs. This act was established to reduce the risk of children accidentally ingesting harmful substances, such as medications, by making packaging more difficult for children to open.

Child-resistant packaging is designed to be significantly more challenging for young children while still being accessible to adults, reflecting the dual aim of protecting vulnerable populations while ensuring that necessary medications remain usable for those who require them. This act underscores the importance of safety in pharmaceutical practices, particularly in preventing accidental poisonings in children.

In contrast, the Prescription Drug Marketing Act primarily focuses on the regulation of the distribution of prescription drugs and the prevention of counterfeit medications. The Kefauver-Harris Amendment deals with drug efficacy and safety following the thalidomide tragedy, emphasizing the need for rigorous testing before approval. The NDC Numbering Act is mainly concerned with standardizing drug identification numbers, without any specific focus on the packaging requirements aimed at child safety.